Pharmaceutical News

RSS

Lower dose of avosentan drug may provide more favorable results in diabetes patients

The drug avosentan substantially reduces urinary protein loss in people with type 2 diabetes and kidney disease, but the drug causes serious side effects, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

18 Feb 2010

FDA approves Rituxan-FC combination therapy for CLL

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec announced today the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab) in combination with fludarabine and cyclophosphamide (FC) for people with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL).

18 Feb 2010

GeoVax Labs presents results of preclinical study on prototype HIV/AIDS vaccine at CROI

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus), today announced that it presented the results of a preclinical study on a prototype HIV/AIDS vaccine at the Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

18 Feb 2010

Rituxan, intended for patients with CLL receives FDA approval

The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.

18 Feb 2010

OPKO Health acquires Pharmacos Exakta

OPKO Health, Inc. today announced that it has completed the acquisition of Pharmacos Exakta, S.A. de C.V. (“Pharmacos Exakta”), a privately-owned Mexican pharmaceutical company engaged in the manufacture, marketing and distribution of ophthalmic and other pharmaceutical products for government and private markets since 1957. OPKO acquired Pharmacos Exakta, including a manufacturing facility owned by an affiliate, for cash and shares of OPKO Common Stock.

18 Feb 2010

Medline Industries signs exclusive distribution agreement with Derma Sciences for BIOGUARD Barrier Dressings

Derma Sciences, Inc., a specialty medical device and pharmaceutical company focused on advanced wound care, today announced that it has signed an exclusive distribution agreement with Medline Industries for sales of one of its key products – BIOGUARD™ Barrier Dressing – into the acute care market. Medline is the 2nd leading provider of traditional wound care products into Acute Care facilities, with over 800 sales representatives. Sales will begin this month.

18 Feb 2010

NPG becomes official media partner to the 2010 WIN Symposium

Nature Publishing Group (NPG) is the official media partner to the 2010 WIN (Worldwide Innovative Networking) Symposium, it was announced today. The second annual WIN Symposium, which will be held in the Palais des Congrès, Paris, 7–9 July 2010, will bring together hundreds of oncology researchers from around the world to discuss how best to tailor therapies for patients with cancer.

18 Feb 2010

Patient-centered medical home concept to benefit pharmaceutical industry

HealthLeaders-InterStudy, a leading provider of managed care market intelligence, reports that the pharmaceutical industry stands to gain from the patient-centered medical home concept that continues to gain traction across the country. According to the recent New England Health Plan Analysis, medical home projects seek to maintain costs and improve health through better treatment compliance, including prescription drug regimens.

18 Feb 2010

Combination therapy that delays nursing home admission for AD earns 43% patient share in U.S. and 30% in Europe

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe Alzheimer's disease, a combination therapy that delays nursing home admission at 19 months would earn 43 percent patient share, according to surveyed U.S. neurologists. In comparison, in Europe, such an agent would earn a slightly lower patient share of 30 percent, according to surveyed European neurologists. This lower share estimate is possibly a result of higher price sensitivity of European markets.

18 Feb 2010

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

Catalyst Pharmaceutical Partners, Inc. announced today that it was selected by both the Scientific and Business Advisory Boards of the Epilepsy Therapy Project to present at the 2010 Epilepsy Pipeline Update Conference, an in-depth, two day forum to be held February 25-26, 2010, at the Hyatt Embarcadero Hotel in San Francisco.

18 Feb 2010

Aptuit develops proprietary production screen to understand API and drug formulations

Aptuit, Inc., today announced that it has developed a proprietary production screen to enable a better understanding of active pharmaceutical ingredients (API) and drug formulations earlier in the product lifecycle. The production screen applies advanced theoretical developments in solid-state chemistry to address challenges at the most critical interfaces in the drug development process.

18 Feb 2010

Study demonstrates once-a-week TB drug is as effective as daily dose

Researchers at the Council for Scientific and Industrial Research (CSIR) are one step closer to providing Tuberculosis (TB) sufferers with a once-a-week medicinal regime rather than their current daily doses.

18 Feb 2010

Anti-seizure medication prevents seizures in patients following bleeding stroke: Study

A study by researchers at the University of Cincinnati Neuroscience Institute at University Hospital supports the use of an alternative medication to prevent seizures in patients who have suffered a life-threatening traumatic brain injury or bleeding stroke.

18 Feb 2010

Medication therapy management programs for Aetna Medicare members

Aetna today announced that members who enroll in its 2010 Medicare plans will have access to enhanced services called medication therapy management (MTM) aimed at helping them safely and effectively take medications prescribed by their physician. MTM, which will be delivered by Mirixa Corporation, brings together pharmacists, patients, physicians and other health care professionals to help patients with their medications.

18 Feb 2010

Cannabis promising for certain pain-related medical conditions, CMCR presents findings to California legislature

Researchers from the University of California's Center for Medicinal Cannabis Research (CMCR) have found "reasonable evidence that cannabis is a promising treatment" for some specific, pain-related medical conditions. Their findings, presented today to the California legislature and public, are included in a report available on the CMCR web site at http://www.cmcr.ucsd.edu

18 Feb 2010

FDA issues Complete Response Letter for Horizant in treatment of RLS

GlaxoSmithKline and XenoPort, Inc. Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).

18 Feb 2010

Taking zinc supplements reduces otitis media in healthy children: No clear evidence

A new Cochrane review did not find clear evidence that taking zinc supplements reduces the occurrence of middle ear infections or otitis media in healthy children.

18 Feb 2010

FDA warns about drug mix-ups; drug maker agrees to name change to avoid confusion

The U.S. Food and Drug Administration today warned consumers about the potential for serious side effects from mistakenly using Maalox Total Relief instead of other Maalox products. The two products are intended for the relief of different symptoms and contain different active ingredients.

18 Feb 2010

Ibuprofen may reduce risk of Parkinson's disease, says study

New research shows people who regularly take ibuprofen may reduce their risk of developing Parkinson's disease, according to a study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010.

18 Feb 2010

Media examine fight against counterfeit drugs

The Wall Street Journal reports on the recent shutdown of a counterfeit drug ring in Syria, while highlighting a broader problem with counterfeit medicines in the Middle East. Authorities intercepted "millions of dollars worth of breast cancer, leukemia and other medicines … At least 65 people were detained; it couldn't be learned if they were charged. A trial date hasn't yet been set," according to the newspaper, which notes that the drug ring distributor's activities had also penetrated into some public health systems, "particularly in Iraq."

18 Feb 2010

Pharmaceutical News

Lower dose of avosentan drug may provide more favorable results in diabetes patients

FDA approves Rituxan-FC combination therapy for CLL

GeoVax Labs presents results of preclinical study on prototype HIV/AIDS vaccine at CROI

Rituxan, intended for patients with CLL receives FDA approval

OPKO Health acquires Pharmacos Exakta

Medline Industries signs exclusive distribution agreement with Derma Sciences for BIOGUARD Barrier Dressings

NPG becomes official media partner to the 2010 WIN Symposium

Patient-centered medical home concept to benefit pharmaceutical industry

Combination therapy that delays nursing home admission for AD earns 43% patient share in U.S. and 30% in Europe

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

Aptuit develops proprietary production screen to understand API and drug formulations

Study demonstrates once-a-week TB drug is as effective as daily dose

Anti-seizure medication prevents seizures in patients following bleeding stroke: Study

Medication therapy management programs for Aetna Medicare members

Cannabis promising for certain pain-related medical conditions, CMCR presents findings to California legislature

FDA issues Complete Response Letter for Horizant in treatment of RLS

Taking zinc supplements reduces otitis media in healthy children: No clear evidence

FDA warns about drug mix-ups; drug maker agrees to name change to avoid confusion

Ibuprofen may reduce risk of Parkinson's disease, says study

Media examine fight against counterfeit drugs

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News